Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma

Omar Al-Odat; Max von Suskil; Robert Chitren; Weam Elbezanti; Sandeep Srivastava; Tulin Budak-Alpddogan; Subash Jonnalagadda; Bharat Aggarwal; Manoj Pandey

doi:10.3389/fphar.2021.699629

Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma

Omar Al-Odat
, Max von Suskil
, Robert Chitren
, Weam Elbezanti
, Sandeep Srivastava
, Tulin Budak-Alpddogan
, Subash Jonnalagadda
, Bharat Aggarwal
, Manoj Pandey

Rowan University

Research output: Contribution to journal › Review article › peer-review

Abstract

Multiple myeloma (MM) is a plasma cells neoplasm. The overexpression of Bcl-2 family proteins, particularly myeloid cell leukemia 1 (Mcl-1), plays a critical role in the pathogenesis of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor prognosis of MM. Thus, inhibition of the Mcl-1 protein considered as a therapeutic strategy to kill the myeloma cells. Over the last decade, the development of selective Mcl-1 inhibitors has seen remarkable advancement. This review presents the critical role of Mcl-1 in the progression of MM, the most prominent BH3 mimetic and semi-BH3 mimetic that selectively inhibit Mcl-1, and could be used as single agent or combined with existing therapies.

Original language	English (US)
Article number	699629
Journal	Frontiers in Pharmacology
Volume	12
DOIs	https://doi.org/10.3389/fphar.2021.699629
State	Published - Jul 19 2021

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.3389/fphar.2021.699629

Cite this

@article{3d24bfcfcfa549f3b59f3500dc7d6ff6,

title = "Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma",

abstract = "Multiple myeloma (MM) is a plasma cells neoplasm. The overexpression of Bcl-2 family proteins, particularly myeloid cell leukemia 1 (Mcl-1), plays a critical role in the pathogenesis of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor prognosis of MM. Thus, inhibition of the Mcl-1 protein considered as a therapeutic strategy to kill the myeloma cells. Over the last decade, the development of selective Mcl-1 inhibitors has seen remarkable advancement. This review presents the critical role of Mcl-1 in the progression of MM, the most prominent BH3 mimetic and semi-BH3 mimetic that selectively inhibit Mcl-1, and could be used as single agent or combined with existing therapies.",

author = "Omar Al-Odat and \{von Suskil\}, Max and Robert Chitren and Weam Elbezanti and Sandeep Srivastava and Tulin Budak-Alpddogan and Subash Jonnalagadda and Bharat Aggarwal and Manoj Pandey",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Al-Odat, von Suskil, Chitren, Elbezanti, Srivastava, Budak-Alpddogan, Jonnalagadda, Aggarwal and Pandey.",

year = "2021",

month = jul,

day = "19",

doi = "10.3389/fphar.2021.699629",

language = "English (US)",

volume = "12",

journal = "Frontiers in Pharmacology",

issn = "1663-9812",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Mcl-1 Inhibition

T2 - Managing Malignancy in Multiple Myeloma

AU - Al-Odat, Omar

AU - von Suskil, Max

AU - Chitren, Robert

AU - Elbezanti, Weam

AU - Srivastava, Sandeep

AU - Budak-Alpddogan, Tulin

AU - Jonnalagadda, Subash

AU - Aggarwal, Bharat

AU - Pandey, Manoj

PY - 2021/7/19

Y1 - 2021/7/19

N2 - Multiple myeloma (MM) is a plasma cells neoplasm. The overexpression of Bcl-2 family proteins, particularly myeloid cell leukemia 1 (Mcl-1), plays a critical role in the pathogenesis of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor prognosis of MM. Thus, inhibition of the Mcl-1 protein considered as a therapeutic strategy to kill the myeloma cells. Over the last decade, the development of selective Mcl-1 inhibitors has seen remarkable advancement. This review presents the critical role of Mcl-1 in the progression of MM, the most prominent BH3 mimetic and semi-BH3 mimetic that selectively inhibit Mcl-1, and could be used as single agent or combined with existing therapies.

AB - Multiple myeloma (MM) is a plasma cells neoplasm. The overexpression of Bcl-2 family proteins, particularly myeloid cell leukemia 1 (Mcl-1), plays a critical role in the pathogenesis of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor prognosis of MM. Thus, inhibition of the Mcl-1 protein considered as a therapeutic strategy to kill the myeloma cells. Over the last decade, the development of selective Mcl-1 inhibitors has seen remarkable advancement. This review presents the critical role of Mcl-1 in the progression of MM, the most prominent BH3 mimetic and semi-BH3 mimetic that selectively inhibit Mcl-1, and could be used as single agent or combined with existing therapies.

UR - https://www.scopus.com/pages/publications/85111928888

UR - https://www.scopus.com/pages/publications/85111928888#tab=citedBy

U2 - 10.3389/fphar.2021.699629

DO - 10.3389/fphar.2021.699629

M3 - Review article

SN - 1663-9812

VL - 12

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

M1 - 699629

ER -

Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this